Abstract
The topical application of therapeutic agent has shown promising efficacy in the treatment of skin disorders. The siRNA based therapies have been used for treatment of various disorders including skin diseases. The topical delivery of siRNA based therapies has opened new perspectives for the treatment of skin disorders. The use of siRNA is limited due to the rapid degradation and poor cellular uptake. Also, the stratum corneum, the top layer of skin is the major barrier for the delivery of topical agents. There is unmet need for efficient topical formulation that will deliver the siRNA to the site of action and also overcome the associated siRNA delivery limitations. The topical delivery of siRNA has been achieved using viral or nonviral methods, and the combination of non-viral methods with an active permeation method such as iontophoresis, sonophoresis or microneedles for the treatment of skin disorders. These delivery approaches have been tested in a preclinical setup and few cases the results have shown promise for clinical trials. This review provides an update on the advances in the non-viral delivery approaches for siRNA delivery for skin disorders and use of various delivery approaches for efficient delivery at the disease site.
Keywords: siRNA, skin disorders, topical, nanoparticle.
Current Pharmaceutical Design
Title:Progress in Topical siRNA Delivery Approaches for Skin Disorders
Volume: 21 Issue: 31
Author(s): Mohammed Aldawsari, Mahavir B. Chougule and R. Jayachandra Babu
Affiliation:
Keywords: siRNA, skin disorders, topical, nanoparticle.
Abstract: The topical application of therapeutic agent has shown promising efficacy in the treatment of skin disorders. The siRNA based therapies have been used for treatment of various disorders including skin diseases. The topical delivery of siRNA based therapies has opened new perspectives for the treatment of skin disorders. The use of siRNA is limited due to the rapid degradation and poor cellular uptake. Also, the stratum corneum, the top layer of skin is the major barrier for the delivery of topical agents. There is unmet need for efficient topical formulation that will deliver the siRNA to the site of action and also overcome the associated siRNA delivery limitations. The topical delivery of siRNA has been achieved using viral or nonviral methods, and the combination of non-viral methods with an active permeation method such as iontophoresis, sonophoresis or microneedles for the treatment of skin disorders. These delivery approaches have been tested in a preclinical setup and few cases the results have shown promise for clinical trials. This review provides an update on the advances in the non-viral delivery approaches for siRNA delivery for skin disorders and use of various delivery approaches for efficient delivery at the disease site.
Export Options
About this article
Cite this article as:
Aldawsari Mohammed, Chougule B. Mahavir and Babu Jayachandra R., Progress in Topical siRNA Delivery Approaches for Skin Disorders, Current Pharmaceutical Design 2015; 21 (31) . https://dx.doi.org/10.2174/1381612821666150911093606
DOI https://dx.doi.org/10.2174/1381612821666150911093606 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery
Current Drug Targets Cardiac Tumors: Clinical Perspective and Therapeutic Considerations
Current Drug Targets Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers
Current Drug Targets Meta Analysis of Advanced Cancer Survival Data Using Lognormal Parametric Fitting: A Statistical Method to Identify Effective Treatment Protocols
Current Pharmaceutical Design Ovarian Cancer Biomarkers: A Focus on Genomic and Proteomic Findings
Current Genomics Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Intrinsic Disorder in Male Sex Determination: Disorderedness of Proteins from the Sry Transcriptional Network
Current Protein & Peptide Science Astrocytes: Adhesion Molecules and Immunomodulation
Current Drug Targets Immune Cell-derived Vesicles: Modulators and Mediators of Inflammation
Current Pharmaceutical Design Adenovirus-based Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Editorial [ Hot Topic:Biology in Anticancer Treatment (Guest Editor: Bruno Vincenzi)]
Current Cancer Drug Targets Incidental Extracardiac Findings on Coronary Computed Tomography Angiography: A Pictorial Review of Imaging Findings
Current Medical Imaging TGF Beta Inhibition for Cancer Therapy
Current Cancer Drug Targets Is α7-nAChR a Possible Target for Lung Cancer and Malignant Pleural Mesothelioma Treatment?
Current Drug Targets CSPG4 in Cancer: Multiple Roles
Current Molecular Medicine Roles of Tumor Microenvironment in Hepatocelluar Carcinoma
Current Cancer Therapy Reviews Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy
Current Drug Metabolism Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets Development of NGR-Based Anti-Cancer Agents for Targeted Therapeutics and Imaging
Anti-Cancer Agents in Medicinal Chemistry Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets